SLC5A2 and hydrops fetalis: The EMPA-REG OUTCOME trial [3] and CANVAS Program [4] demonstrated that SGLT2 inhibitor treatment significantly reduced major CV adverse events and hospitalization for heart failure (HF) in patients with T2D at high risk of CV events.